In this week's Homerun Slides, we conclude with a look at the future direction of diabetes apps.

The CTLA4 gene on chromosome 2q33.2 encodes a transmembrane co-receptor expressed on the surface of T cells. This functions as a negative regulator of T-cell activation via interaction with the B7 molecule on antigen-presenting cells (Figure 30.3). The G allele of the +49A/G SNP in exon 1 of CTLA4 has been implicated as a susceptibility marker for T1DM, but was rejected as a causal SNP by a fine-mapping study, which showed that its effect could be explained by more strongly associated variants in a 6.1 kb noncoding region, 3′ of the gene.

Only a minority of U.S. adults with prediabetes eligible to participate in a national diabetes prevention program are doing so.

Pioglitazone shown to be effective for secondary prevention in patients who have had a stroke and have prediabetes, according to a post hoc analysis of the IRIS trial.

Women with type 2 diabetes are at increased risk of developing breast cancer.

In this Exclusive Interview transcript, Tim Dunn talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about Abbott's research on CGM use and how the FreeStyle Libre system is helping a variety of patients with diabetes.

In this Exclusive Interview, Tim Dunn talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the work of Abbott on CGM use and how the FreeStyle Libre system is helping a variety of patients with diabetes.

In part 1 of this Exclusive Interview, Tim Dunn discusses the various abstracts on CGM use as presented by Abbott in a talk with Diabetes in Control Publisher Steve Freed.

In part 2 of this Exclusive Interview, Tim Dunn talks with Diabetes in Control Publisher Steve Freed about the CGM as more than a tool but as a form of treating diabetes.

In part 3 of this Exclusive Interview, Tim Dunn addresses ways for patients to handle the cost of a CGM in a talk with Diabetes in Control Publisher Steve Freed.